Congratulations to the Volumetric team on their acquisition by 3D Systems!
Continue Reading >Juno Diagnostics, a San Diego based genetic diagnostics company in the Bioverge portfolio, just raised a $25 million Series A round led by Perceptive Xontogeny Venture Fund in May 2021.
Continue Reading >Invest in Eysz to accelerate personalized treatments with improved patient outcomes for 70M+ epilepsy patients worldwide.
Continue Reading >Congratulations to our portfolio company Echo on their acquisition by CELLINK!
Continue Reading >Ancilia is a computational bio-platform company that engineers phage-resistant bacterial therapeutics utilizing CRISPR/Cas to treat microbiome-linked diseases including inflammatory bowel disease (IBD) and immunotherapy-associated colitis.
Continue Reading >Octagon Therapeutics is developing targeted small molecules with selectivity towards autoimmune diseases
Continue Reading >IVIVA Medical was founded with the goal of developing autologous tissue constructs as a solution to end-state renal disease (ESRD). The IVIVA team is leveraging emerging complementary technologies in tissue engineering, 3D additive manufacturing, and stem cell biology in order to realize the potential of regenerative medicine to end donor organ shortage.
Continue Reading >HepaTx is developing revolutionary stem cell-based therapies for liver disease
Continue Reading >The Suggestic platform helps partners build beautiful and powerful apps, create personalizable programs that bundle with their own diagnostic and nutrition offerings, and the technology that allows them to incorporate advanced functionality and the most comprehensive data sources. All at a fraction of the time and cost.
Continue Reading >Atherosclerosis is the leading cause of heart attacks, strokes, and vascular heart disease and, as a result, is the #1 cause of death . Repair Biotechnologies is developing a gene therapy to reverse atherosclerosis by providing immune cells with a novel way to break down cholesterol.
Continue Reading >